Compare Southwest Airlines Co (LUV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs TransMedics Group Inc — how do they compare? Southwest Airlines Co trades at $41.66 (market cap $20.23B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Southwest Airlines Co is far larger — about 7.4× TransMedics Group Inc's market cap, and Southwest Airlines Co pays a 1.74% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and TransMedics Group Inc for 24 Days on average.
| LUV | TMDX | |
|---|---|---|
Market Cap | $20.23B | $2.74B |
Volume | 14,560,422 | 949,331 |
Sector | Industrials | Health |
52-Week High | $54.80 | $150.42 |
52-Week Low | $29.67 | $61.99 |
Typical Hold Time | 65 Days | 24 Days |
Enterprise Value | $23.33B | $3.13B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.36, down 0.86% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported revenue of $28.06B in 2025 with a net income margin of 2.78%, while valuation ratios like P/E of 25.85 and P/S of 0.72 suggest moderate pricing. Recent earnings have been volatile, with a significant beat in Q2 2026 but a miss in Q1 2026, and the upcoming Q3 2026 results on October 21, 2026, are highly anticipated amid a commercial transformation driving record unit revenue.
The outlook for LUV is cautiously optimistic, with analyst consensus pointing to a $49.61 price target and 42% buy ratings, but risks include high fuel costs, competitive pressures from rivals like United and American, and macroeconomic volatility. Investment opportunity lies in the successful execution of new fare structures and ancillary services, projected to boost EBIT, though bearish technical signals and net cash outflows require careful monitoring for sustained shareholder value.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
